Head & Neck Cancer Trials

 

• STUDY10899
  
  Pembrolizumab In Combination With Anti platelet Therapy For Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
  
  To determine if anti-platelet therapy (acetylsalicylic acid, clopidogrel) combined with anti-PD-1 immunotherapy (pembrolizumab) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) is able to induce a more favorable immunologic response profile than immunotherapy alone.
  
  Study Information

  ---

  
  

• STUDY16596
  
  An Open Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
  
  RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
  
  Study Information

  ---

  
  

• STUDY15227
  
  A Phase 2, randomized, open label three arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK 7902) in combination with pembrolizumab (MK 3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD 1/PD L1 inhibitors) (LEAP 009)
  
  To compare lenvatinib + pembrolizumab combination therapy and SOC chemotherapy with respect to ORR per RECIST 1.1 as assessed by BICR.
  
  Study Information

  ---

  
  

• STUDY17022
  
  First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
  
  The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
  
  Study Information

  ---

  
  

• STUDY17262
  
  Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial
  
  Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.
  
  Study Information

  ---